{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:47:07Z","timestamp":1790192827551,"version":"4.1.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873432"],"award-info":[{"award-number":["81873432"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Transplant-associated thrombotic microangiopathy (TA-TMA) is a dangerous and life-threatening complication in patients undergoing hematopoietic stem cell transplantation (HSCT). Eculizumab has been used in the treatment of TA-TMA, and several studies have confirmed the benefit of Eculizumab in patients with TA-TMA. However, the results remain controversial. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of Eculizumab for TA-TMA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>We searched PubMed and Embase for studies on the efficacy and safety of Eculizumab in TA-TMA patients. Efficacy outcomes consisted of overall response rate (ORR), complete response rate (CRR), and survival rate at the last follow-up (SR). Safety outcomes were adverse events (AEs), including infection, sepsis, impaired liver function, infusion reactions, and death.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 116 patients from six studies were subjected to meta-analysis. The pooled estimates of ORR, CRR, and SR for TA-TMA patients were 71% (95% CI: 58\u201382%), 32% (95% CI: 11\u201356%), and 52% (95% CI: 40\u201365%), respectively. Only one patient presented with a severe rash, and infection was the most common AEs. The main causes of death were infection and GvHD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Current evidence suggests that Eculizumab improves SR and ORR in patients with TA-TMA and that Eculizumab is well tolerated. However, the number of studies is limited, and the findings are based mainly on data from observational studies. Higher quality randomized controlled trials and more extensive prospective cohort studies are needed.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2020.564647","type":"journal-article","created":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T07:13:50Z","timestamp":1611126830000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":51,"title":["Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis"],"prefix":"10.3389","volume":"11","author":[{"given":"Rui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqian","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,1,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16457","article-title":"Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy","volume":"189","author":"Epperla","year":"2020","journal-title":"Br J Haematol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/s1473-0502(02)00020-4","article-title":"Transplantation-associated thrombotic microangiopathy is associated with transplantation from unrelated donors, acute graft-versus-host disease and venoocclusive disease of the liver","volume":"27","author":"Daly","year":"2002","journal-title":"Transfus Apher Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","author":"Jodele","year":"2014","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","article-title":"A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury","volume":"29","author":"Jodele","year":"2015","journal-title":"Blood Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3324\/haematol.10699","article-title":"Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group","volume":"92","author":"Ruutu","year":"2007","journal-title":"Haematologica"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181f24e8d","article-title":"Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation","volume":"90","author":"Cho","year":"2010","journal-title":"Transplantation"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-321315","article-title":"Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"118","author":"Laskin","year":"2011","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2018.04.003","article-title":"Complement in Pathophysiology and Treatment of Transplant-Associated Thrombotic Microangiopathies","volume":"55","author":"Jodele","year":"2018","journal-title":"Semin Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-782870","article-title":"Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GvHD","volume":"130","author":"Gloude","year":"2017","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3092-9","article-title":"Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation","volume":"96","author":"Qi","year":"2017","journal-title":"Ann Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12202","article-title":"Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy","volume":"161","author":"Peffault de Latour","year":"2013","journal-title":"Br J Haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.97","article-title":"Recovery from life-threatening transplantation-associated thrombotic microangiopathy using eculizumab in a patient with very severe aplastic anemia","volume":"49","author":"Okano","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"B13","article-title":"Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments","volume":"12","author":"Chapin","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2012.214","article-title":"French Study Group for a HCG. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"B15","volume-title":"Soliris (eculizumab) [prescribing information]","year":"2018"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int"},{"key":"B17","year":"2014"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N. Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13127","article-title":"Eculizumab for transplant-associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients","volume":"101","author":"Rudoni","year":"2018","journal-title":"Eur J Haematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.840","article-title":"Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors","volume":"25","author":"Schoettler","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.08.019","article-title":"Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation: A Comparison of Eculizumab Therapy and Conventional Therapy","volume":"23","author":"Bohl","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B22","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern. Med"},{"key":"B23","unstructured":"The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta\u2013analysis\n            WellsGA\n            SheaB\n            O\u2019ConnellD"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000601","article-title":"Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC","volume":"99","author":"de Fontbrune","year":"2015","journal-title":"Transplantation"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/1076029615599439","article-title":"Eculizumab in Transplant-Associated Thrombotic Microangiopathy","volume":"23","author":"Dhakal","year":"2017","journal-title":"Clin Appl Thromb Hemost"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004218","article-title":"Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab","volume":"135","author":"Jodele","year":"2020","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21352","article-title":"Outcomes of plasma exchange in patients with transplant-associated thrombotic microangiopathy based on time of presentation since transplant","volume":"30","author":"Mulay","year":"2015","journal-title":"J Clin Apher"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703414","article-title":"Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation","volume":"29","author":"Corti","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06588.x","article-title":"Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab","volume":"137","author":"Au","year":"2007","journal-title":"Br J Haematol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.01.009","article-title":"Early Increase in Complement Terminal Pathway Activation Marker sC5b-9 Is Predictive for the Development of Thrombotic Microangiopathy after Stem Cell Transplantation","volume":"24","author":"Horvath","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2019.07.016","article-title":"Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry","volume":"4","author":"Rondeau","year":"2019","journal-title":"Kidney Int Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.03.032","article-title":"Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination","volume":"22","author":"Jodele","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018020321","article-title":"Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GvHD","volume":"2","author":"Wall","year":"2018","journal-title":"Blood Adv"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0293-3","article-title":"High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease","volume":"54","author":"Kraft","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.03.002","article-title":"Circulating Heme Oxygenase-1 and Complement Activation in Transplant-Associated Thrombotic Microangiopathy","volume":"25","author":"Pan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B36","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev.pharmtox.46.120604.141046","article-title":"Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway","volume":"47","author":"Kensler","year":"2007","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.12.565","article-title":"Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"20","author":"Jodele","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.253","article-title":"Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy","volume":"52","author":"Dhakal","year":"2017","journal-title":"Bone Marrow Transplant"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.564647\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T07:14:03Z","timestamp":1611126843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.564647\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,20]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2020.564647"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.564647","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,20]]},"article-number":"564647"}}